Clinical utility of liquid biopsy for monitoring patients with NRAS-mutant medium-to-giant congenital melanocytic nevi

J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e200-e203. doi: 10.1111/jdv.18584. Epub 2022 Oct 13.

Authors

Neus Calbet-Llopart^{1

2}, Gemma Tell-Martí^{1

2}, Judit Mateu¹, Marta Feito³, Silvestre Martínez⁴, Susana Puig^{1

2}, Josep Malvehy^{1

2}, Cristina Carrera^{1

2}, Joan A Puig-Butillé^{2

5}

Affiliations

¹ Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
² Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.
³ Department of Pediadric Dermatology, Hospital Universitario La Paz-UAM, Madrid, Spain.
⁴ Dermatology Department, Complejo Hospitalario Carlos Haya, Málaga, Spain.
⁵ Molecular Biology CORE, Biomedical Diagnostic Center (CDB), Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

PMID: 36151998
DOI: 10.1111/jdv.18584

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

GTP Phosphohydrolases / genetics
Humans
Liquid Biopsy
Membrane Proteins
Nevus, Pigmented* / pathology
Skin Neoplasms* / pathology

Substances

NRAS protein, human
Membrane Proteins
GTP Phosphohydrolases

Supplementary concepts

Melanocytic nevus syndrome, congenital

Grants and funding